Rasburicase Treatment in Chronic Gouty Arthritis

Chronic Gout Clinical Trial

Official title:
Efficacy and Safety of Rasburicase in the Treatment of Chronic Gouty Arthritis: A Multicenter Randomized Controlled Study

Status Recruiting

Clinical Trial Summary

The study will establish efficacy and safety of rasburicase in chronic gouty arthritis

Clinical Trial Description

The study hypothesis is that the proportion of patients who achieved the primary endpoint after 12 weeks of treatment with rasburicase combined with oral urate-lowering therapy is superior to 12 weeks of treatment with oral urate-lowering therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05312268
Study type	Interventional
Source	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact	Qianhua Li, M.D.&Ph.D
Phone	862081332572
Email	liqianhua@mail.sysu.edu.cn
Status	Recruiting
Phase	Phase 4
Start date	June 15, 2022
Completion date	April 15, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04596540` - A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II	Phase 3
Completed	`NCT02956278` - The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics	Phase 4
Completed	`NCT03905512` - A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy	Phase 2
Completed	`NCT04762498` - A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)	Phase 4
Completed	`NCT04513366` - A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy	Phase 3